Xigen SA
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Private
- Established
- 2002-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.xigenpharma.com
Clinical Trials
4
Active:0
Completed:4
Trial Phases
3 Phases
Phase 1:1
Phase 2:1
Phase 3:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 3
2 (50.0%)Phase 1
1 (25.0%)Phase 2
1 (25.0%)Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation and Pain
- First Posted Date
- 2015-07-24
- Last Posted Date
- 2017-01-24
- Lead Sponsor
- Xigen SA
- Target Recruit Count
- 309
- Registration Number
- NCT02508337
- Locations
- 🇺🇸
Ora, Andover, Massachusetts, United States
Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation
- First Posted Date
- 2014-09-09
- Last Posted Date
- 2017-01-24
- Lead Sponsor
- Xigen SA
- Target Recruit Count
- 339
- Registration Number
- NCT02235272
Efficacy and Safety of XG-104 for the Treatment of Dry Eye
- First Posted Date
- 2014-09-09
- Last Posted Date
- 2016-07-18
- Lead Sponsor
- Xigen SA
- Target Recruit Count
- 260
- Registration Number
- NCT02235259
- Locations
- 🇺🇸
Andover Eye Associates, Andover, Massachusetts, United States
Safety, Tolerability and PK of a Single iv Infusion of 10, 40, and 80 µg/kg XG-102 Administered to Healthy Volunteers
- First Posted Date
- 2012-04-04
- Last Posted Date
- 2012-04-04
- Lead Sponsor
- Xigen SA
- Target Recruit Count
- 24
- Registration Number
- NCT01570205
- Locations
- 🇨🇭
Covance Clinical Research, Allschwil, BS, Switzerland
News
No news found